Available Technologies
# of Displayed Technologies: 2 / 2
Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
- College: College of Medicine (COM)
- Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
- Licensing Officer: He, Panqing
Novel gapmers targeting HOXB-AS3 for Acute Myeloid Leukemia Treatment
TS-037979 — A novel treatment for acute meloid leukemia.
The expression of long non-coding RNAs (lncRNAs) in older adults with cytogenetically normal acute myeloid leukemia (CN-AML) is reported to have prognostic significance. lncRNA HOXB-AS3 was identified among the top up-regulated lncRNAs in NPM1-mutated CN-AML cases. Aberrant expression of HOX genes…
- College: College of Medicine (COM)
- Inventors: Garzon, Ramiro; Dorrance, Adrienne; Kauppinen, M.Sc., Ph.D., Sakari; Lee, Robert; Papaioannou, Dimitrios
- Licensing Officer: He, Panqing
